| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
45,530,000 |
| Market
Cap: |
67.38(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6 - $1.73 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Passage Bio is a genetic medicines company focused on developing therapies for monogenic central nervous system disorders. Co. is developing PBGM01, which utilizes a proprietary AAVhu68 capsid for the treatment of GM1 gangliosidosis. Co. is also developing PBFT02, which utilizes an AAV1 capsid for the treatment of frontotemporal dementia-progranulin deficiency. Co. is also developing PBKR03, which utilizes a proprietary AAVhu68 capsid for the treatment of Krabbe disease. Co. has various programs in the research stage under its license agreement with the Trustees of the University of Pennsylvania including: PBML04 for metachromatic leukodystrophy and PBAL05 for amyotrophic lateral sclerosis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,192,577 |
1,192,577 |
| Total Buy Value |
$0 |
$0 |
$1,001,765 |
$1,001,765 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
3,108 |
45,406 |
56,859 |
65,593 |
| Total Sell Value |
$3,015 |
$41,507 |
$51,586 |
$62,246 |
| Total People Sold |
2 |
3 |
4 |
6 |
| Total Sell Transactions |
2 |
5 |
6 |
9 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2022-01-18 |
4 |
B |
$5.46 |
$626,262 |
I/I |
114,700 |
6,222,323 |
1.5 |
-67% |
|
| Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2022-01-14 |
4 |
B |
$5.60 |
$57,680 |
I/I |
10,300 |
6,107,623 |
1.5 |
-67% |
|
| Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2022-01-13 |
4 |
B |
$5.52 |
$230,736 |
I/I |
41,800 |
6,097,323 |
1.5 |
-68% |
|
| Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2022-01-12 |
4 |
B |
$5.65 |
$565,000 |
I/I |
100,000 |
6,055,523 |
1.5 |
-66% |
|
| Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2022-01-11 |
4 |
B |
$5.53 |
$45,346 |
I/I |
8,200 |
5,955,523 |
1.5 |
-65% |
|
| Quigley Jill M. |
Chief Operating Officer |
• – – |
2021-12-08 |
4 |
OE |
$0.23 |
$16,554 |
D/D |
71,975 |
368,754 |
|
- |
|
| Goldsmith Bruce A |
CEO and President |
• • – |
2021-05-21 |
4 |
B |
$13.12 |
$26,230 |
D/D |
2,000 |
5,983 |
2.81 |
-27% |
|
| Morris Richard Steven |
Chief Financial Officer |
• – – |
2021-05-21 |
4 |
B |
$13.82 |
$30,000 |
D/D |
2,171 |
5,454 |
2.74 |
-27% |
|
| Romano Gary |
Chief Medical Officer |
• – – |
2021-03-15 |
4 |
AS |
$20.95 |
$211,013 |
D/D |
(10,000) |
0 |
|
-39% |
|
| Romano Gary |
Chief Medical Officer |
• – – |
2021-03-15 |
4 |
OE |
$8.07 |
$80,700 |
D/D |
10,000 |
10,000 |
|
- |
|
| Quigley Jill M. |
Chief Operating Officer |
• – – |
2021-01-20 |
4 |
AS |
$30.01 |
$39,011 |
D/D |
(1,300) |
295,284 |
|
-52% |
|
| Quigley Jill M. |
Chief Operating Officer |
• – – |
2021-01-14 |
4 |
S |
$30.10 |
$490,570 |
D/D |
(16,298) |
296,584 |
|
53% |
|
| Countouriotis Athena |
Director |
– • – |
2020-03-24 |
4 |
B |
$14.98 |
$149,750 |
D/D |
10,000 |
18,900 |
2.39 |
13% |
|
| Ratcliffe Liam |
Director |
– • – |
2020-03-03 |
4/A |
B |
$18.00 |
$9,900,000 |
I/I |
550,000 |
2,616,630 |
2.1 |
- |
|
| Ratcliffe Liam |
Director |
– • – |
2020-03-03 |
4/A |
A |
$0.00 |
$0 |
I/I |
2,066,630 |
2,066,630 |
|
- |
|
| Topper James N |
10% Owner |
– – • |
2020-03-03 |
4 |
B |
$18.00 |
$9,900,000 |
D/D |
550,000 |
5,009,219 |
2.45 |
14% |
|
| Topper James N |
10% Owner |
– – • |
2020-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
4,459,219 |
4,459,219 |
|
- |
|
| Heron Patrick J |
Director |
– • • |
2020-03-03 |
4 |
B |
$18.00 |
$9,900,000 |
I/I |
550,000 |
5,009,219 |
2.25 |
14% |
|
| Heron Patrick J |
Director |
– • • |
2020-03-03 |
4 |
A |
$0.00 |
$0 |
I/I |
4,459,219 |
4,459,219 |
|
- |
|
| Islam Saqib |
Director |
– • – |
2020-03-03 |
4 |
B |
$18.00 |
$90,000 |
D/D |
5,000 |
5,000 |
2.39 |
14% |
|
| Yamada Tadataka |
Director |
– • – |
2020-03-03 |
4 |
B |
$18.00 |
$117,000 |
D/D |
6,500 |
656,149 |
2.39 |
14% |
|
| Ratcliffe Liam |
Director |
– • – |
2020-03-03 |
4 |
B |
$18.00 |
$50,400 |
D/D |
2,800 |
2,800 |
2.39 |
14% |
|
| Orbimed Capital Gp Vii Llc |
10% Owner |
– – • |
2020-03-03 |
4 |
A |
$0.00 |
$0 |
I/I |
5,574,023 |
5,947,323 |
|
- |
|
| Countouriotis Athena |
Director |
– • – |
2020-03-03 |
4 |
B |
$18.00 |
$160,200 |
D/D |
8,900 |
8,900 |
2.39 |
14% |
|
| Fotopoulos Alexandros |
Chief Technical Officer |
• – – |
2020-03-03 |
4 |
B |
$18.00 |
$99,000 |
D/D |
5,500 |
5,500 |
2.74 |
14% |
|
61 Records found
|
|
Page 2 of 3 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (0.68%) 
